The Benefit of Radiotherapy/Antiandrogen Combination in Men With Locally Advanced Prostate Cancer

February 18, 2014
Sophie D. Fosså, MD, PhD

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, comments on the benefit of radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

Clinical Pearls

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, comments on the benefit of radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

  • The primary aim of this study was to show a 10% reduction in prostate cancer mortality
  • The final analysis (median follow-up of 11 years) showed about an 11% reduction in prostate cancer-specific mortality
  • The benefit could have been even greater, as elderly men die of other causes which cannot be affected by treatment, such as cardiovascular disease